Arterial hypertension affects over one billion people around the world, making the prevention and treatment of this disease vital. Despite the efforts made to develop new antihypertensive drugs, few new therapies have become available. Angiotensin-converting enzyme (ACE) inhibitors have heralded major steps forward in the treatment of arterial hypertension and cardiovascular diseases since the first compound of this class, captopril, was approved for clinical use in 1981.
In this review, the authors investigated the patent documents that cite the priority patent for captopril, Squibb’s first blockbuster, or any other patent from its patent family. The documents were classified into the following: new compounds, new compositions, treatment, process (preparation of a compound), use of a compound, and process for the preparation of an intermediate. Therefore, the readers can identify potential innovations in the field.
The pharmaceutical sector has attempted to provide significant technological developments on anti-hypertensive drugs based on the patenting of captopril, including the development of new compositions further comprising an ACE inhibitor and other antihypertensive agent, along with dual action compounds, novel molecules with dual activity. The target is to find a new agent with better blood pressure-lowering efficacy, improved safety and good tolerability proﬁle.
Author(s): Adelaide Maria de Souza Antunes, Rafaela Di Sabato Guerrante, Jorge de Paula Costa Ávila, Flavia Maria Lins Mendes
Organization(s): Federal University of Rio de Janeiro (UFRJ)/National Institute of Industrial Property (INPI-Brazil)
Source: Expert Opinion on Therapeutic Patents